Arxxant’s Fate In Question After FDA Requests Additional Trial
Lilly may seek a development partner for the diabetic retinopathy treatment to collect the three additional years of efficacy data sought by FDA.
Lilly may seek a development partner for the diabetic retinopathy treatment to collect the three additional years of efficacy data sought by FDA.